Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT07266298
First seen Jan 05, 2026 · Last updated May 12, 2026 · Updated 20 times
Summary
This early-phase study tests a new treatment called NW-101C, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells carrying a specific marker (PRAME). The study enrolls up to 24 adults with advanced solid tumors who have exhausted standard options. The main goals are to check safety and find the best dose, while also watching for any tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID METASTATIC TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer hosptial
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.